Dr. van Haeringen Laboratorium B.V.

H436 Haemophilia A (Factor VIII) (patent owner)

Background

Haemophilia A is a coagulation disorder caused by defects in the large and complex coagulation factor VIII (FVIII) gene. The bleeding predisposition associated with haemophilia A results from a deficiency or dysfunction of FVIII, with the severity depending on the amount of residual FVIII activity.

Test specific information

This test is patented in certain countries. We offer our clients two options for this test because we are not allowed to perform the test in our laboratory.
Firstly, the test can be ordered through a licensee of the patent owner. In this case, the patent owner requires that privacy sensitive information is provided. Per submitted sample a fully filled out form Form ‘Permission providing personal and animal data to patent owner ‘ is required. As a second option, the test can be forwarded to a partner laboratory in non-patented territory.

Between these two options, a price difference is in place which is caused by the royalties costs on the test. The tests performed by both labs are technical identical.

Age

The genetic factor is continuously present, and will always be visible.

Turnaround time

The Turnaround Time (TAT) depends on various factors, such as the shipment time of your sample to the test location, the test method(s) and whether the tests are performed completely or partially by a Partner Lab or Patent owner.

The TAT of tests performed at our facilities is normally 10 working days after receipt of the sample at the testing laboratory (VHL, VHP or Certagen). For tests performed by a Partner Laboratory (so-called "partner lab test") or patent owner, the TAT is at least 20 working days after receipt of your sample. Because the shipment time to our Partner Labs or patent owner may vary due to factors we cannot influence, the mentioned 20 working days are therefore an estimate.

PLEASE NOTE
Sometimes it is necessary to re-run your sample. We call this a retest. In that case, the TAT will of course be extended.

Location of disease or trait

This disease affects the composition of the blood, consequently influencing the coagulation of blood.

Breed dependence

This DNA test is available for the following breeds: German Shepherd, Irish setter, Miniature Schnauzer. Additional information is available in the Frequently Asked Questions (FAQ).

Sample type

For this DNA test we accept the following materials: Blood EDTA, Blood Heparin, Tissue, Semen, Swab. Please contact Dr. Van Haeringen Laboratorium if you wish to submit other material as listed.

Result

The following results are possible for a female: the mode of inheritance is based on recessive or dominant patterns.

The following results are possible for a male:
- A male animal has the sex chromosome Y and a healthy allel. When used in breeding, this animal will not become affected by the disease, nor will the disease be inherited to the next generation.
- A male animal has the sex chromosome Y and a disease allel. When used in breeding, this animal will become affected by the disease. Also, male offspring will receive the Y-chromosome, whereas female offspring will receive the disease allele.

Inheritance

The disease is inherited in an X-chromosomal manner. This means, that female individuals can be free (homozygous normal), affected (homozygous affected) or carrier (heterozygous).

Male individuals carry only one copy of the X-chromosome, which results in the effect that male carriers will also be affected.

Female carriers may spread the disease in a population without showing symptoms themselves. Because of this, it is extremely important to identify carriers correctly to prevent spreading of a disease.

Severity of Disease

-

Code H436

Haemophilia A (Factor VIII) (patent owner)

€ 108,30 (Incl. 21% VAT)
€ 89,50 (Excl. VAT)
Quantity